tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Paradigm Biopharmaceuticals Updates on Phase 3 iPPS Trial

Story Highlights
Paradigm Biopharmaceuticals Updates on Phase 3 iPPS Trial

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Paradigm Biopharmaceuticals ( (AU:PAR) ) has provided an announcement.

Paradigm Biopharmaceuticals held an investor webinar to update on its global Phase 3 clinical trial of iPPS for knee osteoarthritis. The company aims to address unmet medical needs with this therapy, which could significantly impact its market positioning and offer new treatment options for patients with inflammatory diseases.

The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.73 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.

More about Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Ltd. is a late-stage drug development company focused on improving patients’ health by developing pharmaceutical therapies. The company’s current focus is on developing injectable pentosan polysulfate sodium (iPPS) for treating diseases where inflammation is a major factor, such as osteoarthritis.

Average Trading Volume: 861,579

Technical Sentiment Signal: Buy

Current Market Cap: A$159M

See more insights into PAR stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1